Advances of cancer stem cell markers in colorectal cancer

doi:10.3760/cma.j.issn.1673-422X.2016.06.019

Abstract

Abstract: Cancer stem cells (CSCs) markers are specific molecules to identify CSCs. Recent findings demonstrate that CSCs markers associated with colorectal cancer mainly include CD133, CD29, CD166, CD44, Nanog, etc. These markers can take park in the initiation and progression of cancers by various molecular mechanisms, which have the potential to be used as therapeutic targets as well as prognostic indicators.

Key words: Colorectal neoplasms, Neoplastic stem cells, Tumor markers, biological, Prognosis

Liu Liguo, Yan Xuebing, Shan Zezhi, Jin Zhiming. Advances of cancer stem cell markers in colorectal cancer[J]. Journal of International Oncology, 2016, 43(6): 468-471.

References

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61(2): 69-90. DOI: 10.3322/caac.20107. ［2］ Fanali C, Lucchetti D, Farina M, et al. Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives［J］. World J Gastroenterol, 2014, 20(4):923-942. DOI: 10.3748/wjg.v20.i4.923. ［3］ Ulasov IV, Nandi S, Dey M, et al. Inhibition of sonic hedgehog and notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy［J］. Mol Med, 2011, 17(1/2): 103-112. DOI: 10.2119/molmed.2010.00062. ［4］ Corbo C, Orrù S, Gemei M, et al. Protein crosstalk in CD133+ colon cancer cells indicates activation of the Wnt pathway and upregulation of SRp20 that is potentially involved in tumorigenicity［J］. Proteomics, 2012, 12(12): 2045-2059. DOI: 10.1002/pmic.201100370. ［5］ Sahlberg SH, Spiegelberg D, Glimelius B, et al. Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells［J］. PLoS One, 2014, 9(4): e94621. DOI: 10.1371/journal.pone.0094621. ［6］ Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors［J］. J Clin Invest, 2008, 118(6): 2111-2120. ［7］ Horst D, Scheel SK, Liebmann S, et al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer［J］. J Pathol, 2009, 219(4): 427-434. DOI: 10.1002/path.2597. ［8］ Huang XF, Chen JZ. Obesity, the PI3K/Akt signal pathway and colon cancer［J］. Obes Rev, 2009, 10(6): 610-616. DOI: 10.1111/j.1467-789X.2009.00607.x. ［9］ Song J, Zhang J, Wang J, et al. β1 integrin mediates colorectal cancer cell proliferation and migration through regulation of the hedgehog pathway［J］. Tumour Biol, 2015, 36(3): 2013-2021. DOI: 10.1007/s13277-014-2808-x. ［10］ Zhu Y, Feng Y, Liu H, et al. CD4+ CD29+ T cells are blamed for the persistent inflammatory response in ulcerative colitis［J］. Int J Clin Exp Pathol, 2015, 8(3): 2627-2637. ［11］ Vassos N, Rau T, Merkel S, et al. Prognostic value of β1 integrin expression in colorectal liver metastases［J］. Int J Clin Exp Pathol, 2014, 7(1): 288-300. ［12］ Chappell PE, Garner LI, Yan J, et al. Structures of CD6 and its ligand CD166 give insight into their interaction［J］. Structure, 2015, 23(8): 14261436. DOI: 10.1016/j.str.2015.05.019. ［13］ Weichert W, Knsel T, Bellach J, et al. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival［J］. J Clin Pathol, 2004, 57(11): 1160-1164. DOI: 10.1136/jcp.2004.016238. ［14］ Tachezy M, Zander H, Gebauer F, et al. Activated leukocyte cell adhesion molecule (CD166)its prognostic power for colorectal cancer patients［J］. J Surg Res, 2012, 177(1): e15-20. DOI: 10.1016/j.jss.2012.02.013. ［15］ Horst D, Kriegl L, Engel J, et al. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer［J］. Cancer Invest, 2009, 27(8): 844-850. DOI: 10.1080/07357900902744502. ［16］ Ni C, Zhang Z, Zhu X, et al. Prognostic value of CD166 expression in cancers of the digestive system: a systematic review and metaanalysis［J］. PLoS One, 2013, 8(8): e70958. DOI: 10.1371/journal.pone.0070958. ［17］ Du L, Wang H, He L, et al. CD44 is of functional importance for colorectal cancer stem cells［J］. Clin Cancer Res, 2008, 14(21): 6751-6760. DOI: 10.1158/10780432.CCR-08-1034. ［18］ Paulis YW, Huijbers EJ, Van Der Schaft DW, et al. CD44 enhances tumor aggressiveness by promoting tumor cell plasticity［J］. Oncotarget, 2015, 6(23): 19634-19646. DOI: 10.18632/oncotarget.3839. ［19］ Galizia G, Gemei M, Del Vecchio L, et al. Combined CD133/CD44 expression as a prognostic indicator of diseasefree survival in patients with colorectal cancer［J］. Arch Surg, 2012, 147(1): 18-24. DOI: 10.1001/archsurg.2011.795. ［20］ Li XD, Ji M, Wu J, et al. Clinical significance of CD44 variants expression in colorectal cancer［J］. Tumori, 2013, 99(1): 88-92. DOI: 10.1700/1248.13794. ［21］ Katoh S, Goi T, Naruse T, et al. Cancer stem cell marker in circulating tumor cells: expression of CD44 variant exon 9 is strongly correlated to treatment refractoriness, recurrence and prognosis of human colorectal cancer［J］. Anticancer Res, 2015, 35(1): 239-244. ［22］ Hong I, Hong SW, Chang YG, et al. Expression of the cancer stem cell markers CD44 and CD133 in colorectal cancer: an immunohistochemical staining analysis［J］. Ann Coloproctol, 2015, 31(3): 84-91. DOI: 10.3393/ac.2015.31.3.84. ［23］ Mato Prado M, Frampton AE, Stebbing J, et al. Gene of the month: NANOG［J］. J Clin Pathol, 2015, 68(10): 763-765. DOI: 10.1136/jclinpath-2015-203238. ［24］ Zhang J, Espinoza LA, Kinders RJ, et al. NANOG modulates stemness in human colorectal cancer［J］. Oncogene, 2013, 32(37): 4397-4405. DOI: 10.1038/onc.2012.461. ［25］ Palla AR, Piazzolla D, Abad M, et al. Reprogramming activity of NANOGP8, a NANOG family member widely expressed in cancer［J］. Oncogene, 2014, 33(19): 25132519. DOI: 10.1038/onc.2013.196. ［26］ Meng HM, Zheng P, Wang XY, et al. Overexpression of Nanog predicts tumor progression and poor prognosis in colorectal cancer［J］. Cancer Biol Ther, 2010, 9(4): 295302. DOI: 10.4161/cbt.9.4.10666. ［27］ Xu F, Dai C, Zhang R, et al. Nanog: a potential biomarker for liver metastasis of colorectal cancer［J］. Dig Dis Sci, 2012, 57(9): 2340-2346. DOI: 10.1007/s10620-012-2182-8. ［28］ Jeter CR, Yang T, Wang J, et al. Concise review: NANOG in cancer stem cells and tumor development: an update and outstanding questions［J］. Stem Cells, 2015, 33(8): 2381-2390. DOI: 10.1002/stem.2007. ［29］ Lieto E, Galizia G, Orditura M, et al. CD26positive/CD326negative circulating cancer cells as prognostic markers for colorectal cancer recurrence［J］. Oncol Lett, 2015, 9(2): 542-550. DOI: 10.3892/ol.2014.2749. ［30］ Kraus S, Shapira S, Kazanov D, et al. Predictive levels of CD24 in peripheral blood leukocytes for the early detection of colorectal adenomas and adenocarcinomas［J］. Dis Markers, 2015,2015: 916098. DOI: 10.1155/2015/916098. ［31］ Yan X, Yan L, Su Z, et al. Zincfinger protein Xlinked is a novel predictor of prognosis in patients with colorectal cancer［J］. Int J Clin Exp Pathol, 2014, 7(6): 3150-3157. ［32］ Dai X, Ge J, Wang X, et al. OCT4 regulates epithelialmesenchymal transition and its knockdown inhibits colorectal cancer cell migration and invasion［J］. Oncol Rep, 2013, 29(1): 155-160. DOI: 10.3892/or.2012.2086. ［33］ Shan ZZ, Yan XB, Yan LL, et al. Overexpression of Tbx3 is correlated with epithelialmesenchymal transition phenotype and predicts poor prognosis of colorectal cancer［J］. Am J Cancer Res, 2015, 5(1): 344-353. ［34］ Lundberg IV, LfgrenBurstrm A, Edin S, et al. SOX2 expression is regulated by BRAF and contributes to poor patient prognosis in colorectal cancer［J］. PLoS One, 2014, 9(7): e101957. DOI: 10.1371/journal.pone.0101957.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[6]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[7]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[8]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[9]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[10]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[11]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[12]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[13]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[14]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[15]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.